Open Journal Systems
An Analysis of Histamine 2 Receptor Antagonists and a Proposal for Lafutidine
FDA Requests Removal of All Ranitidine Products (Zantac) from the Market. U.S. Food and Drug Administration. 2020 April 1. https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market Accessed October 1st, 2020.
Shye R. Famotidine in Shortage Due to Heartburn Medication Recalls and COVID-19 Research. GoodRx. 2020 May 21. https://www.goodrx.com/blog/famotidine-shortage-from-heartburn-medication-recalls-and-covid-19-research/ Accessed October 1st, 2020.
A Review of Histamine Receptors. Tocris Bioscience. 2019 Jul 23. https://www.news-medical.net/whitepaper/20190723/A-Review-of-Histamine-Receptors.aspx Accessed October 1st, 2020.
Aguilera-Castro L, Prados-de-Argila-de-Martin C, Martinez-Albillos A. Practical considerations in the management of proton-pump inhibitors. University of Alcala. 2016 Mar; 108(3): 145-53. PubMed PMID: 26666270. https://online.reed.es/Revistas/REED_2016_108_3/Contenido/pdf/vol108num3_en_7.pdf Accessed October 1st, 2020.
Stogar (lafutidine) [package insert]. Tokyo, Japan: UCB Japan Co., Ltd.; Revised: April 2005. https://www.ucb.com/_up/ucb_com_products/documents/STOGAR-April2005(050414)_tcm62-3741_tcm81-8593.pdf Accessed October 1st, 2020.
Namikawa T, Munekage E, Maeda H, et al. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. Anticancer Res. 2014 Dec; 34(12): 7297-301. http://ar.iiarjournals.org/content/34/12/7297.long Accessed October 1st, 2020.
Shimatani T, Inoue M, Kuroiwa T et al. Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine. Dig Dis Sci. 2006 Jan; 51(1): 114-120. PubMed PMID: 16416222. file:///C:/Users/Matthew%20Buchfellner/Downloads/Shimatani2006_Article_LafutidineANewlyDevelopedAntiu%20(2).pdf Accessed October 1st, 2020.
Tanaka M, Bamba M, Kamiko A et al. Pharmacological and therapeutic properties of lafutidine (stogar and protecadin), a novel histamine H2 receptor antagonist with gastroprotective activity. J of Japanese Pharmacol. 2001 Jun; 117(6): 377-86. PubMed PMID: 11436515. https://www.jstage.jst.go.jp/article/fpj/117/6/117_6_377/_article/-char/ja/ Accessed October 1st, 2020.
Isomoto H, Inoue K, Furusu H et al. Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. WOL. 2003 March; 8(2): 111-119. PubMed PMID: 12662378. https://onlinelibrary.wiley.com/doi/epdf/10.1046/j.1523-5378.2003.00131 Accessed October 1st, 2020.
Ohara S, Haruma K, Kinoshita Y, Kusano M. A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis. J Gastroenterol. 2010 Dec;45(12):1219-27. doi: 10.1007/s00535-010-0283-8. Epub 2010 Jul 15. PMID: 20632193. Accessed October 1st, 2020.